“OTOH from yesterday’s call it sounds like NAS
Post# of 148179
(Total Views: 476)
Posted On: 12/11/2020 10:36:30 AM
Re: Boatbuilder #67862
“OTOH from yesterday’s call it sounds like NASH could be more profitable.“
Yes, NASH could be very profitable, but the NASH indication is still some time away. The NASH phase 2 trial has only 90 patients and is designed to demonstrate MOA and help design a larger phase 3 trial. I once dug deeply into NASH trials and I believe that phase 3 trials can last anywhere from 1-2 years. CYDY will be lucky to finish the NASH phase 2 trial in 2021 and start a phase 3 in 2022. The SP could see a boost from solid phase 2 results, but approval and revenue is at least 2-3 years in the future.
Yes, NASH could be very profitable, but the NASH indication is still some time away. The NASH phase 2 trial has only 90 patients and is designed to demonstrate MOA and help design a larger phase 3 trial. I once dug deeply into NASH trials and I believe that phase 3 trials can last anywhere from 1-2 years. CYDY will be lucky to finish the NASH phase 2 trial in 2021 and start a phase 3 in 2022. The SP could see a boost from solid phase 2 results, but approval and revenue is at least 2-3 years in the future.
(1)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼